Aspen Pharmacare’s CEO, Stephen Saad, has declared that all hands are on deck to overhaul the group’s manufacturing business. He identified the performance of its sterile unit as a significant drag on earnings. This underperformance has caused the market to undervalue the company. This move is part of Aspen’s effort to unlock value for its stakeholders and enhance its market…